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Abstract
Many G protein-coupled receptors have been shown to be sensitive to the presence of
sodium ions (Na+). Using radioligand competition binding assays, we have examined and
compared the effects of sodium ions on the binding affinities of a number of structurally
diverse ligands at human dopamine D2 and dopamine D3 receptor subtypes, which are
important therapeutic targets for the treatment of psychotic disorders. At both receptors, the
binding affinities of the antagonists/inverse agonists SB-277011-A, L,741,626, GR 103691
and U 99194 were higher in the presence of sodium ions compared to those measured in
the presence of the organic cation, N-methyl-D-glucamine, used to control for ionic strength.
Conversely, the affinities of spiperone and (+)-butaclamol were unaffected by the presence
of sodium ions. Interestingly, the binding of the antagonist/inverse agonist clozapine was
affected by changes in ionic strength of the buffer used rather than the presence of specific
cations. Similar sensitivities to sodium ions were seen at both receptors, suggesting parallel
effects of sodium ion interactions on receptor conformation. However, no clear correlation
between ligand characteristics, such as subtype selectivity, and sodium ion sensitivity were
observed. Therefore, the properties which determine this sensitivity remain unclear. How-
ever these findings do highlight the importance of careful consideration of assay buffer com-
position for in vitro assays and when comparing data from different studies, and may
indicate a further level of control for ligand binding in vivo.
Introduction
G protein-coupled receptors (GPCRs) are a large family of seven transmembrane domain cell
surface receptors responsible for regulating most biological processes. They present effective
drug targets with>40% of marketed therapeutics targeting them, and many drug discovery
programs aimed at developing new GPCR-targeting drugs [1,2]. The neurotransmitter
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dopamine elicits its effects through a family of five GPCRs (dopamine D1-D5 receptors) which
are important targets for the treatment of a number of central nervous system disorders. In
particular, the dopamine D2 subtype is a major site of action of antipsychotic drugs used to
treat disorders such as schizophrenia [3–5]. Many antipsychotic drugs also interact with dopa-
mine D3 receptors but the clinical relevance of these interactions remains controversial. How-
ever, D3 antagonists do show particular promise in the treatment of addiction [6].
A number of GPCRs exhibit sensitivity to the presence of sodium ions (Na+) including α2-
adrenoceptors [7], adenosine A1 receptors [8], opiate receptors [9], and dopamine receptors
[10–17]. Some agonists display reduced affinity in the presence of sodium ions, and some
antagonists increased affinity, while the binding of other ligands is unaffected.
Computational modelling and mutational analysis of several GPCRs have suggested the
presence of a sodium binding pocket where sodium ions occupy a site at the centre of a square-
pyramidal network of hydrogen bonds formed by Asp2.50, Ser3.39 and Asn7.45 and Ser7.46 (resi-
due numbering method of [18]) [19–22]. Asp2.50 within TM2 is very highly conserved among
GPCRs and has been shown to be pivotal in the regulation of their sensitivity to sodium ions. It
is believed to interact with the positively charged sodium ions through electrostatic interactions
via its negatively charged carboxylic group [7,10,12,20,21]. Binding of sodium ions within the
pocket is believed to cause a conformational change which allosterically modulates ligand bind-
ing at the orthosteric site [11]. Interestingly, it has been proposed that this interaction causes a
conformational change in the residue Trp6.48 so that it mirrors that seen in the crystal structure
of the partially inactive form of the receptor [22], suggesting that sodium ion sensitivities of dif-
ferent ligands may reflect their affinity for this inactive conformation. Computational analyses
have also suggested that there is an activation-related collapse of the sodium pocket, implicat-
ing a specific role of sodium in the signal transduction mechanism [23].
Herein we have studied the effects of sodium ions on the binding of range of antagonists/
inverse agonists to dopamine D2 and dopamine D3 receptors. Whether the two receptor sub-
types are differentially regulated by these ions could have important ramifications for future
drug development. In order to interrogate the effects of sodium ions using compounds with
different receptor binding properties/interactions, the ligands tested were inclusive of different
chemical classes (S1 Fig) and receptor subtype selectivity. We postulated that differences seen
may help elucidate why different compounds are sensitive/insensitive to the presence of
sodium ions.
Materials and Methods
Materials
[3H]Spiperone (15–30 Ci/mmol) (5 pM—3.5 nM) was obtained from GE Healthcare. Spiperone
hydrochloride (spiperone), (+)-butaclamol hydrochloride ((+)-butaclamol), (S)-(−)-sulpiride
(sulpiride) and clozapine were obtained from Sigma Aldrich Company Ltd. GR 103691, U
99194 maleate (U 99194) and L-741,626 were obtained from Tocris Cookson Ltd. SB-277011-A
was a generous gift fromM.Wood, Psychiatry CEDD, GlaxoSmithKline, Harlow, UK.
Construction of recombinant baculoviruses and BacMam viruses
pCMV5-hD3 plasmid DNA was a generous gift fromM. Caron, Duke University Medical Cen-
tre, Durham, NC, USA. The dopamine D3 receptor sequence was amplified by PCR and sub-
cloned into the pGEM-T Easy vector (Promega, Southampton, UK) from which it was digested
with NotI and sub-cloned into the baculovirus transfer vector, pVL1392 (BD Biosciences,
Oxford, UK). The resultant pVL1392-hD3 plasmid was co-transfected with Baculogold™ viral
DNA (BD Biosciences) in Sf9 insect cells, and underwent homologous recombination to
Sodium Ion Effects at D2 and D3 Receptors
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produce recombinant baculoviruses encoding the human dopamine D3 receptor (D3). Recom-
binant viruses were isolated and purified using plaque assay purification and were amplified by
serial infection of Sf9 cells.
Baculoviruses encoding human dopamine D2S receptor with an N-terminal FLAG epitope
tag (D2) were provided by S. Nickolls, The University of Reading. BacMam viruses encoding
wild-type and D80A mutant D2S receptors with N-terminal FLAG epitope tags (D2 and
D2
D80A, respectively) and wild-type and D75A mutant D3 receptors with N-terminal c myc epi-
tope tags (D3 and D3
D75A, respectively) were provided by J. Fornwald, GlaxoSmithKline.
Cell culture
Sf9 insect cells were cultured, in suspension, in SF-900 II SFM containing L-glutamine (Invitro-
gen) supplemented with penicillin (100U/ml) / streptomycin (100 μg/ml). Cells were incubated
at 28°C on an orbital shaker (125 rpm) and were sub-cultured every two to three days to main-
tain a density of 500,000–5,000,000 cells/ml. Cells were infected with baculovirus (multiplicity
of infection 5–7) at log-phase growth (~1,000,000 cell/ml) and cells collected after 48 hours.
U-2OS cells were cultured, in D-MEM/F-12 (1:1) medium (Invitrogen) supplemented with
FBS (10%) and L-glutamine (2 mM). Cells were incubated at 37°C in a humidified atmosphere
of 5% CO2 and were sub-cultured every three days. Cells were infected with BacMam viruses
(multiplicity of infection 25) at log-phase growth (75% confluence) in media supplemented
with sodium butyrate (5 mM) and cells collected after 24 hours.
Membrane preparation
U-2 OS cells were detached from flasks by incubation with Versene (Invitrogen) after washing
with phosphate buffered saline (PBS). U-2 OS and Sf9 cells were collected by centrifugation
(200g, 10 min) and re-suspended in buffer 1 (20 mMHEPES, 1 mM EDTA, 1 mM EGTA, pH
7.4, 4°C). Cells were then ruptured using an Ultra Turrax1 T25 homogenizer (24,000 min-1,
4 x 5s) and cell debris removed by centrifugation (400g, 5 min, 4°C). The resulting supernatant
was collected and centrifuged (47,800g, 60 min, 4°C) to collect cell membranes. Membrane pel-
lets were resuspended in buffer 1 using an Ultra Turrax1 T25 homogenizer (6,500 min-1, 2 x
5s). The protein concentration of the membrane preparations was determined using the Lowry
method of protein determination [24] with BSA as a reference standard.
Radioligand binding assays
Radioligand saturation binding assays. Membrane proteins prepared from Sf9 cells
expressing dopamine D2 (25 μg) or dopamine D3 receptors (10 μg) were incubated with a
range of concentrations of [3H]spiperone in buffer 2 (20 mMHEPES, 6 mMMgCl2, 1 mM
EDTA, 1 mM EGTA, 0.1% BSA, pH 7.4) supplemented, where appropriate, with 100 mM
NaCl or 100 mM N-methyl-D-glucamine (NMDG). Reactions were performed, in triplicate, in
4 ml LP4 test tubes (1 ml final volume) and were initiated by addition of membrane proteins.
Non-specific binding was determined in the presence of (+)-butaclamol (3 μM). Reactions
were incubated for 3 hours at 25°C and were terminated by rapid filtration through Whatman
glass microfibre GF/C filters using a Brandel cell harvester. After four 3 ml washes with PBS
(4°C) filter discs were transferred to scintillation vials and soaked in 2ml Ultima Gold™ XR
scintillation fluid (Perkin Elmer) for at least 6 hours prior to their radioactivity being deter-
mined by liquid scintillation spectrometry. Specific binding was calculated by subtraction of
non-specific binding and free radioligand concentration, corrected for ligand depletion calcu-
lated. Data were analysed using Prism (Graphpad) and were fitted to hyperbolic equations
describing a one-binding site model.
Sodium Ion Effects at D2 and D3 Receptors
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Radioligand competition binding assays. Membrane protein prepared from U-2 OS cells
(2 μg) or Sf9 cells (25 μg [D2] or 10 μg [D3]) expressing wild-type or mutant receptors was
incubated with a fixed concentration of [3H]spiperone (0.25 nM [D2] or 1 nM [D3]) and a
range of concentrations of competing ligand in buffer 2 (20 mMHEPES, 6 mMMgCl2, 1 mM
EDTA, 1 mM EGTA, 0.1% BSA, pH 7.4) supplemented with dithiothreitol (0.1 nM) and,
where appropriate, 100 mMNaCl or 100 mMNMDG. Non-specific binding was defined using
(+)-butaclamol (3 μM) in place of the competing ligand. Reactions were performed, in tripli-
cate, in 4 ml LP4 test tubes (1 ml final volume) [Sf9] or deep-well 96-well plates (400μl final
volume) [U-2 OS]. Non-specific binding was determined in the presence of (+)-butaclamol
(3 μM) and total binding determined in the absence of competing ligand. Reactions were initi-
ated, incubated, terminated and radioactivity measured as described under ‘Radioligand satu-
ration binding assays’. Data are presented as percentage of total binding, after subtraction of
non-specific binding. Data were analysed using Prism (Graphpad) and were fitted to sigmoidal
equations describing a one-binding site model. Where % inhibition was<100%, parameters
were calculated by data extrapolation.
Data analysis. Statistical significance of differences between binding parameters were cal-
culated by one-way ANOVA followed by Tukey’s post-hoc test, with a value of p<0.05 consid-
ered significant. Before statistical analysis IC50 and, Kd values were converted to their
respective normally distributed negative logarithms (pIC50 and pKd).
Results
The presence of sodium ions does not affect binding of [3H]spiperone to
dopamine D2 or dopamine D3 receptors
In order to determine the effect of sodium ions on the binding of ligands to the dopamine D2
and dopamine D3 receptors, it was first necessary to select a suitable radioligand which inter-
acted with both receptors at high affinity and the binding of which was not itself affected by the
presence of these ions.
Saturation radioligand binding assays were performed using [3H]spiperone, in the presence
of 100 mMNaCl or in the presence of 100 mMNMDG, an organic cation, used to control for
ionic strength (Table 1). At both receptors, [3H]spiperone affinity was not significantly differ-
ent in either buffer condition. Complete removal of monovalent cations from the buffer also
had no effect on the measured affinity of [3H]spiperone at either receptor (p>0.05). Although
the Bmax measured in the presence of NMDG was higher than in the presence of Na+ or
absence of monovalent cations, the choice of buffer composition did not significantly alter
receptor expression levels measured for either receptor (p>0.05). The lack of sodium
Table 1. Saturation analyses of [3H]spiperone binding in the presence or absence of monovalent cations.
D2 D3
Bmax (pmol/mg) pKd
a Bmax (pmol/mg) pKd
a
0.60 ± 0.14 10.09 ± 0.12 (0.08 nM) 4.21 ± 0.64 9.62 ± 0.10 (0.24 nM)
+ NaCl 0.65 ± 0.10 9.92 ± 0.08 (0.12 nM) 5.39 ± 0.43 9.49 ± 0.11 (0.32 nM)
+ NMDG 1.26 ± 0.49 9.76 ± 0.10 (0.17 nM) 4.57 ± 0.48 9.46 ± 0.03 (0.35 nM)
Radioligand saturation binding analyses of [3H]spiperone, to membranes prepared from Sf9 cells expressing D2 or D3 receptors, were measured in the
absence of monovalent cations, in the presence of 100 mM NaCl or in the presence of 100 mM NMDG. Data are mean ± SEM from 4 independent
experiments.
aValues are presented as their negative logarithms (pKd). Corresponding Kd concentrations are shown in parentheses.
doi:10.1371/journal.pone.0158808.t001
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sensitivity and the sub-nanomolar affinity of [3H]spiperone for both receptor subtypes there-
fore makes it a suitable choice of radioligand for this study.
Mutation of Asp2.50 in dopamine D2 and dopamine D3 receptors
abolishes their sodium ion sensitivity
It has been previously demonstrated that Asp2.50 is critical to the sodium ion sensitivity of
many GPCRs, including dopamine D2 receptors, in which mutation of this residue (D80) to
alanine abolishes sodium ion effects [12]. In order to confirm whether mutation of the corre-
sponding residue in the dopamine D3 receptor (D75) also ablates its sodium ion sensitivity,
mutant receptors in which these aspartic acid residues are replaced with alanine were pro-
duced. Sodium sensitivity of the binding of a substituted benzamide (sulpiride) was then exam-
ined. The binding of this class of dopamine receptor antagonists has previously been
demonstrated to be strongly modulated in the presence of sodium ions [12].
The sodium ion sensitivity of the binding of sulpiride to wild-type and mutant receptors
was investigated by performing radioligand competition binding assays with [3H]spiperone in
the presence of NMDG or NaCl (Fig 1). While the affinity of sulpiride binding to the wild-type
dopamine D2 (pIC50 [NaCl] = 7.02 ± 0.25; pIC50 [NMDG] = 5.78 ± 0.19) and D3 receptors
(pIC50 [NaCl] = 6.74 ± 0.13; pIC50 [NMDG] = 5.57 ± 0.03) was significantly increased (15 to
17-fold; p<0.001) in the presence of NaCl, there was no significant difference in affinity mea-
sured in the two buffer conditions at the dopamine D2
D80A (pIC50 [NaCl] = 5.85 ± 0.21; pIC50
[NMDG] = 5.76 ± 0.08) or dopamine D3
D75A (pIC50 [NaCl] = 5.70 ± 0.15; pIC50 [NMDG] =
5.67 ± 0.14) mutant receptors (p>0.05). At the dopamine D2
D80A and D3
D75A mutant recep-
tors, the affinity of sulpride in either buffer condition reflected that measured for the corre-
sponding wild-type receptor in the presence of NMDG.
The presence of sodium ions affects the binding of several antagonists
to dopamine D2 and dopamine D3 receptors
The effect of the presence of sodium ions on the binding of a range of antagonists/inverse ago-
nists to the two receptors was then determined (Fig 2 and Table 2). At both receptors, the bind-
ing affinities of spiperone and (+)-butaclamol were not significantly different in buffers
containing NaCl or NMDG (p>0.05), suggesting that the binding of these ligands is unaffected
by the presence of sodium ions (Fig 2A and Table 2). Conversely, at both receptors, SB-
277011-A, U 99194, GR 103691 and L,741,626 (Fig 2B, 2C and Table 2) all exhibited
Fig 1. Sodium ionsmodulate the binding of sulpride to wild-type dopamine D2 and D3 receptors but
not to mutant dopamine D2
D80A and D3
D75A receptors. Competition analyses of the inhibition of [3H]
spiperone binding to membranes prepared from U-2 OS cells expressing (A) wild-type dopamine D2
receptors (filled symbols)/dopamine D2
D80A mutant receptors (open symbols) or (B) wild-type dopamine D3
receptors (filled symbols)/dopamine D3
D75A mutant receptors (open symbols), by sulpiride, were performed in
the presence of 100 mMNaCl (&/□) or 100 mMNMDG (▲/Δ). Data are mean ± SEM of at least 3
independent experiments.
doi:10.1371/journal.pone.0158808.g001
Sodium Ion Effects at D2 and D3 Receptors
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significantly higher affinities in buffer containing NaCl compared to that containing NMDG.
As affinities measured in the presence of NMDG were not significantly different from those
measured in the absence of any monovalent cations, these effects appear to be specific to the
presence of sodium ions, rather than to changes in ionic strength.
At both receptors, those compounds which exhibited sodium ion sensitivity displayed vary-
ing levels of sodium ion-modulated differences in affinity. These varied from 17-25-fold for
Fig 2. Binding affinities of several inverse agonists/antagonists are affected by the presence of
sodium ions. Competition analyses of the inhibition of [3H]spiperone binding to membranes prepared from
Sf9 cells expressing dopamine D2 (filled symbols) or dopamine D3 receptors (open symbols), by (A)
spiperone, (B) L,741,626, (C) GR 103691 and (D) clozapine, were performed in the absence of monovalent
cations (●/○), in the presence of 100 mMNaCl (&/□) or 100 mMNMDG (▲/Δ). Data are mean ± SEM of at
least 3 independent experiments.
doi:10.1371/journal.pone.0158808.g002
Table 2. Effects of sodium ions and NMDG on the affinity of various antagonists/inverse agonists.
D2 D3
+ NaCl + NMDG + NaCl + NMDG
SB-277011-A 4.78 ± 0.12(16600 nM) 5.25 ± 0.05b(5660 nM) 4.53 ± 0.05(29800 nM) 6.83 ± 0.13(150 nM) 7.42 ± 0.03b(38.3 nM) 6.64 ± 0.03(231 nM)
U 99194 4.25 ± 0.13(55700 nM) 5.02 ± 0.07b(9480 nM) 4.14 ± 0.18(72900 nM) 5.30 ± 0.18(5050 nM) 6.27 ± 0.06b(532 nM) 5.28 ± 0.08(5200 nM)
GR 103691 6.45 ± 0.13(354 nM) 7.22 ± 0.07b(60.3nM) 6.27 ± 0.02(543 nM) 8.97 ± 0.10(1.08 nM) 9.34 ± 0.04b(0.46 nM) 8.64 ± 0.08(2.29 nM)
Spiperone 9.16 ± 0.17(0.70 nM) 9.21 ± 0.05(0.62 nM) 9.14 ± 0.06(0.73 nM) 8.93 ± 0.07(1.18 nM) 8.91 ± 0.03(1.24 nM) 8.72 ± 0.18(1.91 nM)
(+)-butaclamol 8.64 ± 0.04(2.31 nM) 8.53 ± 0.11(2.97 nM) 8.62 ± 0.28(2.38 nM) 7.88 ± 0.12(13.3 nM) 7.82 ± 0.09(15.0 nM) 7.78 ± 0.03(16.8 nM)
L,741,626 5.92 ± 0.14(1200 nM) 7.07 ± 0.07b(86.1 nM) 5.68 ± 0.09(2110 nM) 5.21 ± 0.21(6120 nM) 6.23 ± 0.01b(589 nM) 5.00 ± 0.11(9930 nM)
Clozapine 6.64 ± 0.02b(228 nM) 6.38 ± 0.06(413 nM) 6.40 ± 0.03(395 nM) 6.30 ± 0.03b(500 nM) 6.17 ± 0.11(681 nM) 6.04 ± 0.03(918 nM)
Competition analyses of the inhibition of [3H]spiperone binding, to membranes prepared from Sf9 cells expressing D2 or D3 receptors, by various ligands,
were performed, in the absence of monovalent cations, in the presence of 100 mM NaCl or in the presence of 100 mM NMDG. Data are mean ± SEM of at
least 3 independent experiments. Values are presented as their negative logarithms (pIC50). Corresponding IC50 concentrations are shown in parentheses.
bp< 0.05 (one-way ANOVA, followed by Tukey’s post-hoc test) for comparison with buffer containing NMDG.
doi:10.1371/journal.pone.0158808.t002
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L,741,626 to 5-6-fold, for SB-277011-A (comparing affinities measured in the presence of NaCl
and NMDG). Additionally, although SB-277011-A displayed quantitatively similar sodium
ion-modulated increases in affinity (5-6-fold) at both receptors, the increase in affinity of GR
103691 and L,741,626 at the D3 receptor was more modest than that observed at the D2 recep-
tor, while the increase in affinity of U 99194 was more modest at the D2 receptor (Table 2).
These differences had some effect on the observed rank order of affinity of the compounds at
each receptor measured in the different buffer conditions. An example is, clozapine which dis-
played similar affinity to GR 103691 at the dopamine D2 receptor in the presence of NMDG
(p>0.05) but significantly lower affinity (7-fold) than GR 103691 in the presence of NaCl
(p<0.05) (Table 2).
Interestingly, and in contrast to the sodium ion-modulated effects described above, at both
receptors the affinity of clozapine was similar in the presence of both NaCl and NMDG and
moderately increased (2-fold) upon removal of monovalent cations from the buffer, suggesting
an effect of ionic strength rather than the presence of specific cations on the binding of this
ligand to these receptors (Fig 2D and Table 2).
Discussion
We have examined sodium ion sensitivity of the binding of a range of ligands to dopamine D2
and dopamine D3 receptors. Although prior studies have described the effects of sodium ions
on the binding of ligands to these receptors, the panel of ligands examined, particularly with
respect to the D3 receptor, has been extremely limited [17,25,26]. It was our intention to deter-
mine whether there was any differential regulation of ligand binding to the two receptor sub-
types by sodium ions and if so, whether this was impacted by ligand structure and/or subtype
selectivity. Thus, in the present study, a selection of ligands covering different chemical/thera-
peutic classes and with different selectivity for the two dopamine receptor subtypes were exam-
ined (S1 Fig). In addition, comparisons were made between buffer conditions containing
sodium ions (NaCl), NMDG as a control for ionic strength, or in the absence of monovalent
cations in order to elucidate sodium ion or ionic strength-specific effects.
The binding affinities of some ligands ((+)-butaclamol and spiperone) were unaffected by
the presence of sodium ions at either receptor. Although sodium sensitivity of the binding of
(+)-butaclamol to the D3 receptor has not previously been studied, our observations that the
binding of spiperone to both the D2 and D3 receptors and (+)-butaclamol to the D2 receptor is
not sensitive to the presence of sodium ions are in agreement with previous studies [14,27–29].
Our finding that the number of D2 receptor binding sites labelled by the radioligand [
3H]-spi-
perone is not affected by the presence/absence of sodium ions is also corroborated by a previ-
ous study reporting no effect of these ions on Bmax values in saturation binding experiments
performed using mammalian cells expressing D2 receptors [14].
The binding affinities of other ligands were increased, at both receptors, in the presence of
sodium ions (SB-277011-A, U 99194, GR 103691 and L,741,626). Each of these ligands exhib-
ited differing degrees of sensitivity, with the sodium-induced increases in affinity varying from
5-6-fold (SB-277,011-A) to 17-25-fold (L,741,616). The sodium ion sensitivities of binding of
these ligands to neither the D2 nor D3 receptors have previously been reported. However previ-
ous studies have demonstrated that the affinity of 1,4-disubstituted aromatic piperidine/pipera-
zine compounds (1,4-DAPs) for D2 receptors is increased in the presence of sodium ions and
that this can be attributed to an enhancement of binding pocket accessibility upon sodium
binding [11]. Compounds L,741,626 and GR 103691, utilised in the present study, are both
1,4–DAPs. Therefore, the observed increased in affinity in the presence of sodium ions is
unsurprising. However, it is interesting that the binding of spiperone, a 1,4-DAP analogue with
Sodium Ion Effects at D2 and D3 Receptors
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a spirocyclic lactam attached, is not sensitive to the presence of sodium, while the binding of U
99194, a compound of unrelated structure, does display sodium sensitivity.
Comparisons were made between affinities measured in the presence of NaCl or the organic
cation, NMDG, and indicated that that, in the majority of cases, the effects seen were specific
to the presence of sodium ions and not due to changes in buffer ionic strength, supporting the
theory that many GPCRs contain sodium ion-specific binding pockets. However, it is interest-
ing to note that, although not significantly different, for those ligands which displayed sodium
ions sensitivities the affinities measured in the presence of NMDG were consistently lower
than those measured in the absence of monovalent cations.
Interestingly, the binding affinity of clozapine was not different when compared in condi-
tions containing sodium or NMDG, while removal of monovalent cations resulted in a signifi-
cant increase in binding affinity at both receptors. These data are indicative of a sensitivity to
the buffer ionic strength (or to the general presence of monovalent cations) rather than the
presence of specific cations. However, the effects seen are very modest (only 2-fold) and there-
fore will have limited implications. These data are in agreement with a previous study which
demonstrated that the affinity of clozapine at the D3 receptor is not different in the presence
of either NaCl or NMDG [17]. However, the data in the present study data contradict those
of previous studies in which the affinity of clozapine at the D2 receptor was found to differ
between buffers containing NaCl and NMDG [27,28]. These previous studies present contra-
dictory findings with respect to the effects of sodium ions on clozapine affinity, with both
sodium-induced increases and decreases in affinity being reported. In addition, affinities in
the absence of either cation were not measured, so it is not possible to determine whether
there were also unspecific cation effects, as demonstrated in the present study. The discrepan-
cies noted may be related to the use of cell background used for the measurements with mam-
malian cells being utilised in the previous studies as opposed to the Sf9 cell system employed
here. Furthermore, in some mammalian cell systems, clozapine has been shown to display
binding to two distinct affinity states of the D2 receptor, possibly reflecting its ability to distin-
guish between G protein-coupled and free forms. Indeed, Malmberg et al. reported biphasic
displacement curves for clozapine binding to D2 receptors in their mammalian cell system
[17]. In Sf9 cells, coupling to endogenous G proteins has been shown to be poor [30]. There-
fore, differences in G protein-coupling between these studies may also contribute to the differ-
ences seen.
It has been postulated that the interaction of GPCRs with sodium ions causes a conforma-
tional change to a form that potentially reflects the partially inactive state of the receptor.
Therefore, it would be predicted that the affinities of antagonist / inverse agonist ligands
(believed to stabilize the inactive state of the receptor) would be increased in in the presence of
sodium ions while agonist affinities would be decreased for the same reason. Indeed, such
effects of sodium on agonist/antagonist binding have previously been reported for several
GPCRs [8,9,14,31,32]. However, in the present study, we demonstrate that different antago-
nist/inverse agonist ligands can have differing affinities for the sodium-bound receptor.
Although the affinities of many were increased, others were unaffected or, in the case of cloza-
pine, were decreased in the presence of sodium, indicating that sodium ion sensitivity is not
related to efficacy.
We found that mutation of the conserved aspartate residue, Asp2.50, previously demonstrated
to be pivotal for sodium ion regulation of the D2 receptor [7,12,20–22], also abolished sodium-
induced effects on binding of the substituted benzamide, sulpiride, to the D3 receptor suggesting
a similar mode of interaction with these ions for the two receptors. Binding to both receptors
was also affected by the presence of sodium ions in a similar way, suggesting that sodium ion
interaction causes parallel conformational changes in both subtypes. Therefore, it would be
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predicted that compounds with similar properties and thus similar interactions with the recep-
tors, would be affected in the same way. However, there was no correlation between subtype
selectivity of the compounds and their sensitivity to sodium ions as SB-277011A displayed
dopamine D3 receptor selectivity and L,741,626 dopamine D2 receptor selectivity, but the affini-
ties of both were increased in the presence of sodium ions. Furthermore, SB277011-A, a large
multi-cyclic carboxamide 1,4,-DAP, displays similar sensitivity to sodium ions as U 99194, a
much smaller compound with very little structural similarity. Therefore, it is likely that the
sodium sensitive compounds share binding interactions with sites revealed upon sodium bind-
ing and which are common to the two receptors, while subtype selectivity of these compounds
is determined by interactions with residues not affected by sodium interactions. Indeed, while
the binding sites of both receptors share very high homology, molecular modelling studies have
indicated differences in the extracellular part of the binding pocket which have been predicted
to be involved in conferring compound selectivity for the two receptors [33].
Although the presence of sodium ions affects both receptors in a similar manner, differences
were observed in the degree to which their affinities were altered at the two receptors. Again,
these differences did not correlate with the subtype selectivity of the compounds, but it is inter-
esting to note that the sodium-induced effects on binding of the two structurally related com-
pounds (GR 103691 and L741,626) were both far more modest at the D3 receptor than the D2
receptor. Although the specific properties and interactions which determine sodium ion sensi-
tivity of the compounds remain unclear, further interrogation through molecular docking anal-
ysis may be able to shed light on these effects. Indeed, a recent study used a combination of
binding assays and computational modelling analyses (utilising the published crystal structure
of the D3 receptor reported by Chien et al. [34]) to study the impact of sodium ion binding on
the conformation and ligand binding pocket of D2 and D3 receptors [29]. They found that the
presence of sodium had similar allosteric effects on the ligand binding site of both receptors
and removal of the ion caused a weakening/breaking of an important interaction between the
side chains of the conserved residues, Asp3.32 and Tyr7.43, (located between the sodium binding
pocket and ligand binding site). This interaction is critical for the binding of the sodium sensi-
tive substituted benzamide ligands, sulpiride and eticlopride. Thus, the binding affinity of these
ligands is decreased upon disruption of this bond in the absence of sodium ions, whereas the
more extensive receptor binding interactions of the sodium-insensitive compound, spiperone,
are though to mask these effects [29]. Although the compounds tested in the present study are
structurally unrelated to the substituted benzamide ligands, a similar mechanism may also
account for their sodium sensitivities.
Although the presence of sodium ions was found to affect both receptors in a similar man-
ner, some evidence of differential regulation of the two receptor subtypes by sodium ions was
observed (with relation to the magnitude of the effects seen), but these differences were mini-
mal. However, this study does highlight that assay buffer composition can have a significant
effect on measured ligand affinities. This is an important observation, especially when compar-
ing data from different laboratories and when analysing the pharmacological properties of
potential therapeutics. Modulation of ligand binding by sodium ions may also have physiologi-
cal relevance. For example, in dopaminergic neurons, action potentials result in large transient
fluctuations in intra- and extracellular sodium ion concentrations. Therefore, effects on bind-
ing of exogenous and endogenous compounds in vivo should also be considered.
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